Standard BioTools and SomaLogic update merger presentation; target $300M+ revenue, $80M synergies by 2026

STANDARD BIOTOOLS INC.

All-stock merger: SLGC shareholders receive 1.1100 LAB shares per share; expected close Q1 2024.
Pro-forma combined 2026E revenue >$300M and $80M run-rate cost synergies fully achieved by 2026.
Combined cash at close >$500M; ownership: SLGC ~57%, LAB ~43% (incl. Series B preferred).
Shareholder vote set for Jan 4, 2024; supportive voting agreements from ~16% of LAB and ~1% of SLGC shareholders.
Presentation defends merger against Madryn allegations, citing premium, governance, and reduced execution risk.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.